tbuckley/cabot-search huggingface dataset:
Ceres (Summer)
Authors: M. Therese Southgate
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA (2019)

Treatment of Uncontrolled Type 2 Diabetes 1466Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), improves glycemic control and may also have cardiovascular benefi ts.Rosenstock and colleagues for the PIONEER 3 Investigators randomized 1864 patients who had type 2 diabetes that was uncontrolled by metformin with or without sulfonylurea and found that oral semaglutide, compared with sitagliptin, resulted in signifi cantly greater reductions in hemoglobin A 1c .In an Editorial, Hirsch notes that adding a GLP-1RA to metformin is now recommended for patients with diabetes and atherosclerotic cardiovascular disease who need further glycemic lowering.
Identifying Populations Potentially Exposed to Agricultural Pesticides Using Remote Sensing and a Geographic Information System
Authors: Mary H. Ward, John R. Nuckols, Stephanie J. Weigel, Susan K. Maxwell, Kenneth P. Cantor, Ryan S. Miller
Journal: Environmental Health Perspectives (2000)

Pesticides used in agriculture may cause adverse health effects among the population living near agricultural areas.However, identifring the populations most likely to be exposed is difficult.We conducted a feasibility study to determine whether satellite imagery could be used to recon- stmct historical crop patterns.We used historical Fann Service Agency records as a source of ground reference data to classify a late summer 1984 satellite image into crop species in a three- county area in south central Nebraska.Residences from a population-based epidemiologic study of non-Hodgkin lymphoma were located on the crop maps using a geographic information sys- tem (GIS).Corn, soybeans, sorghum, and alfilfa were the major crops grown in the study area.Eighty-five percent of residences could be located, and of these 22% had one of the four major crops within 500 m of the residence, an intermediate distance for the range of drift effects from pesticides applied in agriculture.We determined the proximity of residences to specific crop species and calculated crop-specific probabilities of pesticide use based on available data.This feasibility study demonstrated that remote sensing data and historical records on crop location can be used to create historical crop maps.The crop pesticides that were likely to have been applied can be estimated when information about crop-specific pesticide use is available.Using a GIS, zones of potential exposure to agricultural pesticides and proximity measures can be deter- mined for residences in a study.
Implanted pump concentrates chemotherapy for liver cancer
Authors: E. R. Gonzalez
Journal: JAMA (1981)

An implantable infusion pump is prolonging survival in hepatic cancer, both primary and metastatic. The pump delivers 100 to 400 times the amount of floxuridine that the liver receives through conventional systemic chemotherapy—without the life-threatening side effects, as only 2% of the drug reaches the systemic circulation. Surgery to implant the pump is somewhat tricky, but ten to 14 days afterwards, patients go home and, if their disease is not too advanced, resume normal lives. The pump, manufactured by Infusaid Corporation, Sharon, Mass, was originally developed by the University of Minnesota's biomedical engineering department for the administration of heparin; it also has been used for insulin delivery. At the University of Michigan Medical Center, Ann Arbor, William D. Ensminger, MD, PhD, associate professor of internal medicine and Burroughs Wellcome Scholar in Clinical Pharmacology, and John Niederhuber, MD, head, Division of Surgical Oncology, began using the device for chemotherapy administration about
SURGERY IN THE TREATMENT OF CEREBRAL VASCULAR ACCIDENTS
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Data and References.
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series
Authors: H. Song, N. Lahood, A. Mostaghimi
Journal: British Journal of Dermatology (2018)

Pyoderma gangrenosum is an uncommon skin condition in which white blood cells, neutrophils, infiltrating the skin lead to destruction and ulceration. Because early treatment is a logical approach to reducing this damage, various different treatment methods have been tried including the use of immunoglobulin, a protein extracted from blood plasma containing antibodies, given by intravenous injection (IVIG). This study is a review of previously published studies using this technique. The authors from Harvard and hospitals in Boston, U.S.A., identified 49 patients who had received this treatment after the failure of other therapies, such as oral corticosteroids and cyclosporine, to improve the condition. Most had at least one underlying disease including cancer or inflammatory bowel disease such as ulcerative colitis. The skin damage affected different body sites such as the lower limbs or trunk. In most cases the patients were also receiving oral corticosteroids at the time of the IVIG treatment. Over half the patients responded completely to the treatment with IVIG in addition to steroids, with a substantial number of the remainder responding in part to this therapy. The most common side effect was nausea or headache although rashes and fever were also seen. Overall these results suggest that it is a potentially useful therapy for patients who have not responded to other medications used to treat this condition.
Gemtuzumab Ozogamicin as Post-Consolidation Therapy Does Not Prevent Relapse In Children with AML. Results of the NOPHO-AML 2004 Study
Authors: Henrik Hasle, Jonas Abrahamsson, Erik Forestier, Shau-Yin Ha, Jesper Heldrup, Kirsi Jahnukainen, Olafur G Jonsson, Birgitte Lausen, Josefine Palle, Bernward Zeller
Journal: Blood (2011)
RECOGNITION OF MEDICAL ORGANIZATION.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medieval Medicine.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smile A While
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE DEATH OF FALSTAFF.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial: Antibiotic diarrhoea.
Journal: BMJ (1975)

Antibiotic diarrhoeaWhen used carefully, antibacterial drugs are relatively free of unwanted effects.Most of those given by mouth do, however, cause gastrointestinal side effects, of which looseness of the bowels is particularly common.'Frank diarrhoea is met less often, but may be severe enough to force withdrawal of the drug.These alterations in bowel function are not confined to antibiotics given by mouth.Systemic chemotherapy may be complicated by fulminating staphylococcal enterocolitis,
Claude Bernard
Authors: Eugene D. Robin
Journal: JAMA (1979)

1978 MARKED the centenary of the death of Claude Bernard, whose ideas have influenced generations of scientists and physicians. During his lifetime he was awarded many honors and was internationally recognized as the supreme example of a physiologist. Despite a personal life filled with much unhappiness, he continued to work productively until his death in Paris on Feb 10, 1878. A specific list of his experimental contributions is extensive. It includes studies on the nature of gastric juice and its role in nutrition, the role of the pancreas in digestion, the relation of the autonomic nervous system to vasomotor control, the physiology of neuromuscular functional transmission (using curare as a probe for these studies), the discovery of glycogen and its relation to glucose metabolism (this work was used to define the general process of internal secretion), the modes of action of carbon monoxide and strychnine, and the invention of both
Factors predictive of response to interferon-α therapy in hepatitis C virus infection
Authors: A Tsubota
Journal: Hepatology (1994)

To determine the patient-dependent and virus-related factors that may predict sustained response to interferon-α therapy, we prospectively evaluated 60 consecutive patients with chronic hepatitis C who received a standardized treatment schedule of interferon-α. Twenty-eight patients achieved a long-term sustained remission, 14 patients had temporary responses during treatment but relapsed after completing it and 14 patients did not respond. Four patients dropped out because of severe side effects and were excluded from evaluation of efficacy. Twenty-one variables were chosen as possible predictors of sustained response and were analyzed by means of multi-variate analysis. Variables related to the hepatitis C virus included genotype and concentration in serum before treatment. The former was determined by means of the polymerase chain reaction with genotype-specific primers for genotypes PT, K1, K2a and K2b, which were deduced from nonstructural region 5 of the hepatitis C virus genome. The latter was measured with a competitive polymerase chain reaction technique. Three variables were statistically significant (p<0.05) on univariate analysis: viral genotype, pretreatment level of viremia and Knodell's fibrosis score. In multivariate analysis viral genotype and Knodell's fibrosis score were correlated independently with a sustained response (p<0.05 for both). Incidence of sustained response was 40% and 91% in patients with genotypes K1 and K2a, respectively. We conclude that with the treatment schedule used, viral genotype was the most useful predictor of a sustained response to treatment with interferon-α. (HEPATOLOGY 1994;19:1088–1094.)
Labels
Authors: Douglas Kamerow
Journal: BMJ (2004)

<h3>Abstract</h3> The latent HIV-1 reservoir containing stably integrated and transcriptionally silent proviruses in CD4+ T cells is a major barrier for virus eradication. Targeted reactivation of the latent reservoir remains a major challenge in establishing a path for an HIV-1 cure. Here, we investigated the possibility of reactivating the HIV-1 reservoir by targeting engineered bacteriophage T4 capsid nanoparticles to reservoir cells. The surface lattice of the 120 x 86 nm phage capsid was arrayed with CD4 binding ligands such as recombinant CD4DARPin or the HIV-1 gp140 envelope protein. When exposed to either PBMCs or the resting CD4+ T cells <i>in vitro</i>, these nanoparticles caused T cells activation without inducing global T cell activation. Furthermore, the nanoparticles reactivated HIV-1 proviral transcription that led to virus assembly and release in the J-Lat cells, a cell line model of HIV-1 latency. Intriguingly, the observed T cell activation and HIV-1 latency reversal did not occur through the classic PKC or NFAT pathways suggesting the involvement of a yet unknown pathway. These studies demonstrate that engineered non-infectious bacteriophages could be potentially exploited for HIV-1 cure and other targeted T cell therapies.
Croatia's brain drain
Journal: BMJ (2005)

experts agree that the obesity epidemic is environmental, but the research has largely ignored this factor. 24It is time to be realistic with individuals about the limited effectiveness of lifestyle interventions and obesity drugs, and to focus on public health interventions rather than individual treatments to halt the obesity epidemic.This article is based on the monograph "What works for obesity?A summary of the evidence behind obesity interventions," which was published in association with Clinical Evidence by the BMJ Publishing Group and commissioned, funded, and distributed by the United Health Foundation..I thank Matt M Davis and Boyd Swinburn for reviewing earlier versions of this manuscript and offering helpful comments.
Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry
Authors: A. Basbaum
Journal: Annual Review of Neuroscience (1984)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
Closing in on the nutrition-immunity link
Authors: P. Gunby
Journal: JAMA (1980)

The relation between nutrition and immune function is intriguing but far from clear, according to research reports presented at the Western Hemisphere Nutrition Congress VI in Los Angeles. At Indiana University School of Medicine, Indian-apolis, Karyl A. Rickard, PhD, RD, and colleagues have been studying hyperalimentation's effects on immunity and tumor growth. Among 28 children with advanced cancer (21 with solid tumors and seven with relapsed leukemia or lymphoma), those given total parenteral nutrition for four weeks had reversal of protein malnutrition, restoration of serum albumin and transferrin concentrations and, usually, a reversal of diminished reactivity to skin test antigens. Rickard cautioned, however, that it is still not possible to say whether prevention or reversal of malnutrition brings about better response to cancer therapy. For one thing, he said, factors other than nutrition may undermine cell-mediated immunity; as examples he cited terminal stage disease, steroid or radiation therapy, or even
The effect of independent practice association plans on use of pediatric ambulatory medical care in one group practice
Authors: P. G. Szilagyi
Journal: JAMA (1990)

We compared the use of pediatric ambulatory medical care of 640 children who switched from a traditional Blue Cross plan to more comprehensive independent practice association plans with that of matched patients who remained with Blue Cross in one large, suburban pediatric practice in Rochester, NY. A quasiexperimental, retrospective cohort design was used. Use of pediatric ambulatory medical care by patients in the independent practice association plan and control patients was determined by medical chart review for 1 year before and 1 year after each patient's switch. During the baseline year, patients who would join the independent practice association plan already had 19% more acute-illness visits than control patients. During the second year, patients in the independent practice association plan averaged 42% more acute-illness visits, 22% more well child—care visits, 93% more chronic-illness visits, 27% more after-hours visits, 53% more weekend visits, 185% more laboratory studies, and 70% more referrals. The shift toward independent practice association plans in this open-market setting increased use of ambulatory medical care for pediatric patients. (<i>JAMA</i>. 1990;263:2198-2203)